Since the introduction of the new pathophysiological concept of pathogen-associated molecular patterns (PAMPS) and alarmins, endotoxin has been recognized as only one of the PAMPS. It is widely accepted that hypercytokinemia plays a pivotal role in the pathophysiology of sepsis. Many kinds of blood purification modalities have been proposed as a therapeutic tool against sepsis, including high-volume continuous hemofiltration whose efficacy has recently been questioned. We report that continuous hemodiafiltration (CHDF) with a cytokine-adsorbing hemofilter (CAH), such as polymethyl methacrylate hemofilter and AN69ST hemofilter (CAH-CHDF), can remove many kinds of cytokines and has been very effective in the treatment of severe sepsis and septic shock. Based on the understanding of the recent pathophysiology, we suggest that CAH-CHDF is an alternate therapy to direct hemoperfusion with endotoxin-adsorbing column in the treatment of sepsis.

Keywords:
Hypercytokinemia, Pathogen-associated molecular patterns, Alarmin, Endotoxin, Cytokine-adsorbing hemofilter, Polymethyl methacrylate hemofilter, AN69ST hemofilter, Continuous hemodiafiltration, High-volume continuous hemofiltration, Direct hemoperfusion with polymyxin-B-immobilized column
1.
Corriveau CC, Danner RL: Endotoxin as a therapeutic target in septic shock. Infect Agents Dis 1993;2:35–43.
2.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Pallavicini FMB, Rottoli F, Giunta F, Ronco C: Early use of polymyxin B hemoperfuson in abdominal septic shock. The EUPHAS randomized controlled trial. JAMA 2009;301:2445–2452.
3.
Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y, Shinozaki K, Hirasawa H: Gram-negative bacteremia induces greater magnitude of inflammatory response than gram-negative bacteremia. Crit Care 2010;14:R27.
4.
Cinel I, Opal SM: Molecular biology of inflammation and sepsis. A primer. Crit Care Med 2009;37:291–304.
5.
Tracey KJ: Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007;117:289–296.
6.
Nakamura M, Oda S, Sadahiro T, Watanabe E, Abe R, Nakada T, Morita Y, Hirasawa H: Correlation between high blood IL-6 level, hyperglycemia, and glucose control in septic patients. Crit Care 2012;16:R58.
7.
Di Carlo JV, Alexander SR: Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 2005;28:777–786.
8.
Nakada T, Hirasawa H, Oda S, Shiga H, Matsuda K: Blood purification for hypercytokinemia. Transfusion Apher Sci 2006;35:253–264.
9.
Kobe Y, Oda S, Matsuda K, Nakamura M, Hirasawa H: Direct hemoperfusion with cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study. Blood Purif 2007;25:446–453.
10.
Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E: Impact of continuous venovenous hemofiltration on organ failure during early phase of severe sepsis. A randomized controlled trial. Crit Care Med 2009;37:803–810.
11.
Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcome of acute renal failure: a prospective randomized trial. Lancet 2000;356:26–30.
12.
Cornejo R, Downey P, Castro R, Romero C, RegueiraT, Vega J, Castillo L, Andresen M, Dougnac A, Bugedo G, Hernandez G: High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006;32:713–722.
13.
Honore PM, Joannes-Boyau O, Boer W, Collin V: High-volume hemofiltration in sepsis and SIRS: current concepts and future prospects. Blood Purif 2009;28:1–11.
14.
The RENAL Replacement Therapy Study Investigators: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627–1638.
15.
Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH: An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient. An international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010;181:1128–1155.
16.
Kellum JA, Song M, Venkataraman R: Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-ĸB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004;32:801–805.
17.
Rimmele T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E, Goudable J, Etienne J, Chassard D, Bricca G, Allaouchiche B: High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009;24:421–427.
18.
Haase M, Silvester W, Uchino S, Goldsmith D, Davenport P, Tipping P, Boyce N, Bellomo R: A pilot study of high-adsorption hemofiltration in human septic patients. Int J Artif Organs 2007;30:108–117.
19.
Hirasawa H: Indications for blood purification in critical care. Contrib Nephrol 2010;166:21–30.
20.
Yamashita AC, Tomisawa N: Importance of membrane materials for blood purification devices in critical care. Transfusion Apher Sci 2009;40:23–31.
21.
Hirayama Y, Oda S, Wakabayasi K, Sadahiro T, Nakamura M, Watanabe E, Tateishi Y: Comparison of interleukin-6 removal properties among hemofilters consisting of varying membrane materials and surface areas: an in vitro study. Blood Purif 2011;31:18–25.
22.
Matsuda K, Moriguchi T, Harii N, Goto J: Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure. Transfusion Apher Sci 2009;40:49–53.
23.
Ronco C, Kellum JA, Bellomo R, House AA: Potential interventions in sepsis-related acute renal failure. Clin J Am Soc Nephrol 2008;3:531–544.
24.
Hirasawa H, Oda S, Matsuda K: Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol 2007;156:365–370.
25.
Nakada T, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, Hirasawa H: Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med 2008;257–263.
26.
Nakamaura M, Oda S, Sadahiro T, Hirayama Y, Watanabe E, Tateishi Y, Nakada T, Hirasawa H: Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contrib Nephrol 2010;166:73–82.
27.
Matsumura Y, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Watanabe E, Abe R, Nakada T, Tateishi Y, Oshima T, Shinozaki K, Hirasawa H: Treatment of septic shock with continuous HDF using 2 PMMA hemofilters for enhanced intensity. Int J Artif Organs 2012;35:3–14.
28.
Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T: Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 2005;33:89–97.
29.
Martin E, Cruz DN, Monti G, Casella G, Vesconi S, Ranieri VM, Ronco C, Antonelli M: Endotoxin removal: how far from the evidence? The EUPHAS 2 project. Contrib Nephrol 2010;167:119–125.
30.
Sakamoto Y, Mashiko K, Obata T, Matsumoto H, Hara Y, Kutsukata N, Yamamoto Y: Effectiveness of continuous hemodiafiltration using a polymehtylmethacrylate membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock. ASAIO J 2008;54:129–132.
31.
Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson JR: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581–3587.
32.
Piccinni P, Dan M, Carraro R, Lieta E, Marafon S, Zamperetti N, Brendolan A, D’Intini V, Tetta C, Bellomo R, Ronco C: Early isovolemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006;32:80–86.
33.
Boussekey N, Chiche A, Faure K, Devos P, Guery B, d’Escrivan T, Georges H, Leroy O: A pilot study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008;34: 1646–1653.
34.
Vincent JL, Laterre PE, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge n patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400–405.
35.
Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Endo S: Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 2006;10:12–18.
36.
Nakamura T, Sugaya T, Koide H: Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. Shock 2009;31:454–459.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.